Saraiva Ivan E, Ortiz-Soriano Victor M, Mei Xiaonan, Gianella Fabiola G, Woc Winnie Sheu, Zamudio Rodrigo, Kelly Andrew, Gupta Meera, Grigorian Alla Y, Neyra Javier A
Clin Nephrol. 2020 Apr;93(4):187-194. doi: 10.5414/CN109983.
Incident acute kidney injury (AKI) in critically ill patients with acute on chronic liver failure (ACLF) is associated with poor prognosis. The role of continuous renal replacement therapy (CRRT) is not well established for patients with ACLF and AKI.
We conducted a retrospective cohort study to examine clinical outcomes in 66 patients with ACLF and AKI requiring CRRT.
All-cause hospital mortality was 89.4%. Five (7.6%) patients were listed for liver transplantation, of whom 1 (1.5%) was eventually subjected to transplantation. Etiology of AKI included type 1 hepatorenal syndrome (HRS) with or without some degree of acute tubular necrosis (ATN) in 20 (30.3%) patients, and primarily ATN in 46 (69.7%) patients. When evaluated at the time of CRRT initiation, Child-Pugh-Turcotte (CPT) and Model for End-stage Liver Disease (MELD) (area under the receiver operating characteristics curve (AUROC) 0.67 for both) had fair performance for prediction of mortality, whereas Sequential Organ Failure Assessment (SOFA) and Chronic Liver Failure (CLIF)-SOFA performed better for the prediction of mortality (AUROC 0.87 for both). SOFA and CLIF-SOFA also performed well when determined at the time of ICU admission (AUROC 0.86 and 0.85, respectively). Etiology of liver disease or AKI did not influence prognosis.
Critically ill patients with ACLF and AKI requiring CRRT have poor hospital survival, even with provision of extracorporeal support therapy. SOFA and CLIF-SOFA are good prognostic tools of mortality in this susceptible population.
急性慢性肝衰竭(ACLF)危重症患者发生的急性肾损伤(AKI)与预后不良相关。连续性肾脏替代治疗(CRRT)在ACLF合并AKI患者中的作用尚未明确。
我们进行了一项回顾性队列研究,以检查66例需要CRRT的ACLF合并AKI患者的临床结局。
全因住院死亡率为89.4%。5例(7.6%)患者被列入肝移植名单,其中1例(1.5%)最终接受了移植。AKI的病因包括20例(30.3%)患者患有1型肝肾综合征(HRS),伴或不伴有一定程度的急性肾小管坏死(ATN),46例(69.7%)患者主要为ATN。在开始CRRT时进行评估时,Child-Pugh-Turcotte(CPT)和终末期肝病模型(MELD)(两者的受试者操作特征曲线下面积(AUROC)均为0.67)对死亡率的预测表现一般,而序贯器官衰竭评估(SOFA)和慢性肝衰竭(CLIF)-SOFA对死亡率的预测表现更好(两者的AUROC均为0.87)。在重症监护病房(ICU)入院时测定时,SOFA和CLIF-SOFA的表现也很好(AUROC分别为0.86和0.85)。肝病或AKI的病因不影响预后。
即使提供体外支持治疗,需要CRRT的ACLF合并AKI危重症患者的住院生存率仍很低。SOFA和CLIF-SOFA是这一易感人群死亡率的良好预后工具。